PriceTargets.com logo

Intensity Therapeutics, Inc. Common stock - INTS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 155.32%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.70 As of 07/26/2024 01:00 AM ET
▼ -0.15 (-3.09%)
Get New Intensity Therapeutics, Inc. Common stock Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INTS

Analyst Price Target is $12.00
▲ +155.32% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Intensity Therapeutics, Inc. Common stock in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 155.32% upside from the last price of $4.70.

This chart shows the closing price for INTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Intensity Therapeutics, Inc. Common stock. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/11/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$12.00 ➝ $12.00N/A
5/16/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$12.00N/A
3/21/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$12.00N/A
11/14/2023BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$12.00N/A
8/24/2023BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$12.00N/A
7/18/2023BenchmarkInitiated CoverageBuy$12.00N/A
(Data available from 7/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
12/29/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Intensity Therapeutics, Inc. Common stock

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Read More

Today's Range

Now: $4.70
Low: $4.66
High: $4.91

50 Day Range

MA: N/A

52 Week Range

Now: $4.70

Volume

9,802 shs

Average Volume

11,294 shs

Market Capitalization

$64.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Intensity Therapeutics, Inc. Common stock?

The following Wall Street research analysts have issued stock ratings on Intensity Therapeutics, Inc. Common stock in the last year: Benchmark Co..
View the latest analyst ratings for INTS.

What is the current price target for Intensity Therapeutics, Inc. Common stock?

1 Wall Street analysts have set twelve-month price targets for Intensity Therapeutics, Inc. Common stock in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 147.4%. Benchmark Co. has the highest price target set, predicting INTS will reach $12.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $12.00 for Intensity Therapeutics, Inc. Common stock in the next year.
View the latest price targets for INTS.

What is the current consensus analyst rating for Intensity Therapeutics, Inc. Common stock?

Intensity Therapeutics, Inc. Common stock currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INTS will outperform the market and that investors should add to their positions of Intensity Therapeutics, Inc. Common stock.
View the latest ratings for INTS.

What other companies compete with Intensity Therapeutics, Inc. Common stock?

Other companies that are similar to Intensity Therapeutics, Inc. Common stock include Zura Bio, Molecular Partners, Monte Rosa Therapeutics, Caribou Biosciences and Acumen Pharmaceuticals. Learn More about companies similar to Intensity Therapeutics, Inc. Common stock.

How do I contact Intensity Therapeutics, Inc. Common stock's investor relations team?

The company's listed phone number is 203 221 7381 and its investor relations email address is [email protected]. The official website for Intensity Therapeutics, Inc. Common stock is www.intensitytherapeutics.com. Learn More about contacing Intensity Therapeutics, Inc. Common stock investor relations.